Tax deductions for health insurance come under scrutiny
Tax preferences are projected to reduce workers' taxes by $2 trillion over the next decade.
WASHINGTON, D.C.-A presidential tax advisory panel has proposed capping tax deductions for employer-provided healthcare benefits, an idea that is generating protests from both industry and the public.
Current law allows employers to deduct the value of premiums paid for employee health insurance; employees also do not have to count the value of those premiums as taxable income. Such tax preferences for healthcare are huge-projected to reduce workers' taxes by almost $2 trillion over the next decade.
As part of its charge to propose ways to make the federal tax system more fair and efficient, the committee recommended capping deductions for employer-provided health benefits at the maximum amount the federal government pays in premiums for its workers-about $11,000 a year under current policies. The change aims to limit high-cost benefits for the wealthy while doing little to affect low- and middle-income workers.
BENEFITS TAXED OUT
Last month, America's Health Insurance Plans (AHIP) released survey results indicating broad bi-partisan voter opposition to changing the tax status of employer-provided healthcare benefits. Two-thirds of likely Republican and Democratic voters said they oppose eliminating or reducing the employer deduction for healthcare benefits, even if that change is linked to lowering overall tax rates. The main concern of the public is that eliminating or reducing deductions for healthcare benefits will prompt companies to drop their health benefits altogether.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Lifts Safety Restrictions on CAR T Therapies After Reviewing Real-World Data
July 2nd 2025FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine release syndrome and neurological toxicities.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
